Pharmaceuticals, Biotechnology and Life Sciences
The recently hosted CPhI & P-MEC China 2020 – organized by Informa Markets and CCCMHPIE and co-organized by Shanghai Sinoexpo Informa Markets International Exhibition Co., Ltd. – attracted a remarkable 46,157 visits of professional pharma visitors, including 5,105 international attendees taking part online.
LUXEMBOURG–(BUSINESS WIRE)–The increasing diversity of SARS-CoV-2 variants and the potential higher infectivity of some new viral strains, underline the need…
European Commission’s decision on conditional marketing authorization is expected imminently, after the positive CHMP opinion, which will make BNT162b2 if authorized, the first COVID-19 vaccine available in the European Union.
A phase II clinical trial of a treatment for COVID-19 patients is currently starting at the Medical University of Vienna as a sub-study of the Austrian CoronaVirus Adaptive Clinical Trial (ACOVACT), as an academia-industry collaboration (investigator Initiated trial) between Apogenix AG and its scientific consultant Henning Walczak and his teams at the University of Cologne and University College London (UCL).
Baris Erdogan, currently Vice President, Site & Patient Networks, at Clinerion, has been promoted by the Board of Directors to the position of Chief Executive Officer as of January 1st, 2021. After a three-year tenure, Clinerion’s current CEO, Ian Rentsch, has decided to step down for personal reasons and to return to his family in Berlin by the end of January, 2021.
U.S. FDA has authorized mRNA vaccine against COVID-19 for emergency use as total of 200 million doses ordered by the U.S government to date, with an option to purchase up to an additional 300 million doses, while approximately 20 million doses will be delivered by the end of December 2020.
Moderna has received positive recommendation in support of Emergency Use Authorization of its COVID-19 vaccine candidate in USA.
Total of 160 million doses ordered by the European Commission to date CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc. (Nasdaq: MRNA), a biotechnology…
The FDA has accepted and granted priority review for a new supplemental Biologics License Application (sBLA) for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with platinum and fluoropyrimidine based chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic carcinoma of the esophagus and gastroesophageal junction
Moderna has made a deal with the Ministry of Health of Singapore to supply mRNA-1273, Moderna’s vaccine candidate against COVID-19, to support ongoing efforts to secure access to a safe and effective COVID-19 vaccine for the people of Singapore.